nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—sarcoma	0.334	1	CtDrD
Crizotinib—TEK—sarcoma	0.132	0.421	CbGaD
Crizotinib—IGF1R—sarcoma	0.114	0.361	CbGaD
Crizotinib—AURKA—Epirubicin—sarcoma	0.0895	0.546	CbGbCtD
Crizotinib—SRC—sarcoma	0.0688	0.219	CbGaD
Crizotinib—AURKA—Doxorubicin—sarcoma	0.0475	0.29	CbGbCtD
Crizotinib—CYP3A4—Thiotepa—sarcoma	0.00418	0.0255	CbGbCtD
Crizotinib—ABCB1—Dactinomycin—sarcoma	0.00336	0.0205	CbGbCtD
Crizotinib—CYP3A5—Vincristine—sarcoma	0.00318	0.0194	CbGbCtD
Crizotinib—ABCB1—Mitoxantrone—sarcoma	0.003	0.0183	CbGbCtD
Crizotinib—CYP3A5—Etoposide—sarcoma	0.00291	0.0178	CbGbCtD
Crizotinib—ABCB1—Vincristine—sarcoma	0.00207	0.0126	CbGbCtD
Crizotinib—ABCB1—Etoposide—sarcoma	0.00189	0.0116	CbGbCtD
Crizotinib—CYP3A4—Mitoxantrone—sarcoma	0.0018	0.011	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—sarcoma	0.00129	0.00788	CbGbCtD
Crizotinib—CYP3A4—Vincristine—sarcoma	0.00124	0.00756	CbGbCtD
Crizotinib—CYP3A4—Etoposide—sarcoma	0.00113	0.00693	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—sarcoma	0.000774	0.00472	CbGbCtD
Crizotinib—CASK—Teniposide—Etoposide—sarcoma	0.000212	0.117	CbGdCrCtD
Crizotinib—Neutropenia—Mitoxantrone—sarcoma	0.000148	0.00402	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Mitoxantrone—sarcoma	0.000148	0.004	CcSEcCtD
Crizotinib—Weight decreased—Vincristine—sarcoma	0.000148	0.004	CcSEcCtD
Crizotinib—Pneumonia—Vincristine—sarcoma	0.000146	0.00396	CcSEcCtD
Crizotinib—Urinary tract disorder—Thiotepa—sarcoma	0.000145	0.00394	CcSEcCtD
Crizotinib—Urethral disorder—Thiotepa—sarcoma	0.000144	0.00391	CcSEcCtD
Crizotinib—Weight decreased—Mitoxantrone—sarcoma	0.000144	0.00389	CcSEcCtD
Crizotinib—Neuropathy peripheral—Vincristine—sarcoma	0.000142	0.00386	CcSEcCtD
Crizotinib—Pneumonia—Mitoxantrone—sarcoma	0.000142	0.00386	CcSEcCtD
Crizotinib—Abscess—Doxorubicin—sarcoma	0.000138	0.00374	CcSEcCtD
Crizotinib—Eye disorder—Thiotepa—sarcoma	0.000138	0.00373	CcSEcCtD
Crizotinib—Cardiac disorder—Thiotepa—sarcoma	0.000137	0.0037	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Etoposide—sarcoma	0.000135	0.00365	CcSEcCtD
Crizotinib—Mediastinal disorder—Thiotepa—sarcoma	0.000133	0.0036	CcSEcCtD
Crizotinib—Arrhythmia—Thiotepa—sarcoma	0.000131	0.00356	CcSEcCtD
Crizotinib—Hypoaesthesia—Vincristine—sarcoma	0.00013	0.00352	CcSEcCtD
Crizotinib—Bradycardia—Mitoxantrone—sarcoma	0.000129	0.00351	CcSEcCtD
Crizotinib—Urinary tract disorder—Vincristine—sarcoma	0.000129	0.00349	CcSEcCtD
Crizotinib—Malnutrition—Thiotepa—sarcoma	0.000128	0.00347	CcSEcCtD
Crizotinib—Urethral disorder—Vincristine—sarcoma	0.000128	0.00347	CcSEcCtD
Crizotinib—Neutropenia—Etoposide—sarcoma	0.000123	0.00335	CcSEcCtD
Crizotinib—Cardiac disorder—Vincristine—sarcoma	0.000121	0.00328	CcSEcCtD
Crizotinib—Gait disturbance—Epirubicin—sarcoma	0.000121	0.00328	CcSEcCtD
Crizotinib—Vision blurred—Thiotepa—sarcoma	0.000121	0.00327	CcSEcCtD
Crizotinib—Pneumonia—Etoposide—sarcoma	0.000118	0.00321	CcSEcCtD
Crizotinib—Anaemia—Thiotepa—sarcoma	0.000118	0.00321	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Epirubicin—sarcoma	0.000118	0.0032	CcSEcCtD
Crizotinib—Pulmonary embolism—Epirubicin—sarcoma	0.000118	0.0032	CcSEcCtD
Crizotinib—Infestation—Etoposide—sarcoma	0.000118	0.00319	CcSEcCtD
Crizotinib—Infestation NOS—Etoposide—sarcoma	0.000118	0.00319	CcSEcCtD
Crizotinib—Mediastinal disorder—Vincristine—sarcoma	0.000118	0.00319	CcSEcCtD
Crizotinib—Anaemia—Dactinomycin—sarcoma	0.000118	0.00319	CcSEcCtD
Crizotinib—Neuropathy peripheral—Etoposide—sarcoma	0.000115	0.00313	CcSEcCtD
Crizotinib—Leukopenia—Thiotepa—sarcoma	0.000115	0.00311	CcSEcCtD
Crizotinib—Leukopenia—Dactinomycin—sarcoma	0.000114	0.00309	CcSEcCtD
Crizotinib—Arrhythmia—Mitoxantrone—sarcoma	0.000114	0.00308	CcSEcCtD
Crizotinib—Fluid retention—Epirubicin—sarcoma	0.000112	0.00304	CcSEcCtD
Crizotinib—Gait disturbance—Doxorubicin—sarcoma	0.000112	0.00303	CcSEcCtD
Crizotinib—Hepatobiliary disease—Etoposide—sarcoma	0.000111	0.00302	CcSEcCtD
Crizotinib—Neuropathy—Epirubicin—sarcoma	0.000111	0.003	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Doxorubicin—sarcoma	0.000109	0.00296	CcSEcCtD
Crizotinib—Pulmonary embolism—Doxorubicin—sarcoma	0.000109	0.00296	CcSEcCtD
Crizotinib—Dysgeusia—Mitoxantrone—sarcoma	0.000108	0.00294	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000108	0.00294	CcSEcCtD
Crizotinib—Hypoaesthesia—Etoposide—sarcoma	0.000105	0.00285	CcSEcCtD
Crizotinib—Anaemia—Vincristine—sarcoma	0.000105	0.00285	CcSEcCtD
Crizotinib—PLK4—Teniposide—Etoposide—sarcoma	0.000105	0.058	CbGdCrCtD
Crizotinib—Urinary tract disorder—Etoposide—sarcoma	0.000104	0.00283	CcSEcCtD
Crizotinib—Vision blurred—Mitoxantrone—sarcoma	0.000104	0.00283	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—sarcoma	0.000104	0.0576	CbGdCrCtD
Crizotinib—Infection—Thiotepa—sarcoma	0.000104	0.00282	CcSEcCtD
Crizotinib—Oedema—Dactinomycin—sarcoma	0.000104	0.00281	CcSEcCtD
Crizotinib—Fluid retention—Doxorubicin—sarcoma	0.000104	0.00281	CcSEcCtD
Crizotinib—Urethral disorder—Etoposide—sarcoma	0.000104	0.00281	CcSEcCtD
Crizotinib—Infection—Dactinomycin—sarcoma	0.000103	0.00279	CcSEcCtD
Crizotinib—Nervous system disorder—Thiotepa—sarcoma	0.000103	0.00278	CcSEcCtD
Crizotinib—Neuropathy—Doxorubicin—sarcoma	0.000103	0.00278	CcSEcCtD
Crizotinib—Sepsis—Epirubicin—sarcoma	0.000102	0.00278	CcSEcCtD
Crizotinib—Anaemia—Mitoxantrone—sarcoma	0.000102	0.00277	CcSEcCtD
Crizotinib—Leukopenia—Vincristine—sarcoma	0.000102	0.00276	CcSEcCtD
Crizotinib—Skin disorder—Thiotepa—sarcoma	0.000102	0.00275	CcSEcCtD
Crizotinib—Leukopenia—Mitoxantrone—sarcoma	9.9e-05	0.00268	CcSEcCtD
Crizotinib—Eye disorder—Etoposide—sarcoma	9.88e-05	0.00268	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—sarcoma	9.85e-05	0.00267	CcSEcCtD
Crizotinib—Cardiac disorder—Etoposide—sarcoma	9.81e-05	0.00266	CcSEcCtD
Crizotinib—Hepatic function abnormal—Epirubicin—sarcoma	9.8e-05	0.00266	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—sarcoma	9.62e-05	0.0533	CbGdCrCtD
Crizotinib—Hepatic failure—Epirubicin—sarcoma	9.53e-05	0.00258	CcSEcCtD
Crizotinib—Mediastinal disorder—Etoposide—sarcoma	9.53e-05	0.00258	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—sarcoma	9.47e-05	0.00257	CcSEcCtD
Crizotinib—Paraesthesia—Thiotepa—sarcoma	9.39e-05	0.00254	CcSEcCtD
Crizotinib—Oedema—Vincristine—sarcoma	9.27e-05	0.00251	CcSEcCtD
Crizotinib—Infection—Vincristine—sarcoma	9.21e-05	0.0025	CcSEcCtD
Crizotinib—Dyspepsia—Thiotepa—sarcoma	9.2e-05	0.00249	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—sarcoma	9.11e-05	0.00247	CcSEcCtD
Crizotinib—Nervous system disorder—Vincristine—sarcoma	9.09e-05	0.00246	CcSEcCtD
Crizotinib—Decreased appetite—Thiotepa—sarcoma	9.09e-05	0.00246	CcSEcCtD
Crizotinib—Hepatic function abnormal—Doxorubicin—sarcoma	9.07e-05	0.00246	CcSEcCtD
Crizotinib—Oedema—Mitoxantrone—sarcoma	9.03e-05	0.00245	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Thiotepa—sarcoma	9.03e-05	0.00245	CcSEcCtD
Crizotinib—Decreased appetite—Dactinomycin—sarcoma	9.02e-05	0.00245	CcSEcCtD
Crizotinib—Fatigue—Thiotepa—sarcoma	9.01e-05	0.00244	CcSEcCtD
Crizotinib—Dysgeusia—Etoposide—sarcoma	9.01e-05	0.00244	CcSEcCtD
Crizotinib—Infection—Mitoxantrone—sarcoma	8.97e-05	0.00243	CcSEcCtD
Crizotinib—Fatigue—Dactinomycin—sarcoma	8.95e-05	0.00243	CcSEcCtD
Crizotinib—Constipation—Thiotepa—sarcoma	8.94e-05	0.00242	CcSEcCtD
Crizotinib—Shock—Mitoxantrone—sarcoma	8.88e-05	0.00241	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—sarcoma	8.82e-05	0.00239	CcSEcCtD
Crizotinib—Skin disorder—Mitoxantrone—sarcoma	8.77e-05	0.00238	CcSEcCtD
Crizotinib—Diplopia—Epirubicin—sarcoma	8.57e-05	0.00232	CcSEcCtD
Crizotinib—Anaemia—Etoposide—sarcoma	8.51e-05	0.00231	CcSEcCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—sarcoma	8.38e-05	0.0464	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—sarcoma	8.38e-05	0.0464	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—sarcoma	8.38e-05	0.0464	CbGdCrCtD
Crizotinib—Paraesthesia—Vincristine—sarcoma	8.33e-05	0.00226	CcSEcCtD
Crizotinib—Face oedema—Epirubicin—sarcoma	8.27e-05	0.00224	CcSEcCtD
Crizotinib—Body temperature increased—Thiotepa—sarcoma	8.27e-05	0.00224	CcSEcCtD
Crizotinib—Leukopenia—Etoposide—sarcoma	8.24e-05	0.00223	CcSEcCtD
Crizotinib—Body temperature increased—Dactinomycin—sarcoma	8.2e-05	0.00222	CcSEcCtD
Crizotinib—AURKA—Teniposide—Etoposide—sarcoma	8.2e-05	0.0454	CbGdCrCtD
Crizotinib—Paraesthesia—Mitoxantrone—sarcoma	8.11e-05	0.0022	CcSEcCtD
Crizotinib—Loss of consciousness—Etoposide—sarcoma	8.09e-05	0.00219	CcSEcCtD
Crizotinib—Decreased appetite—Vincristine—sarcoma	8.06e-05	0.00218	CcSEcCtD
Crizotinib—Dyspnoea—Mitoxantrone—sarcoma	8.05e-05	0.00218	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Vincristine—sarcoma	8e-05	0.00217	CcSEcCtD
Crizotinib—Fatigue—Vincristine—sarcoma	7.99e-05	0.00217	CcSEcCtD
Crizotinib—Dyspepsia—Mitoxantrone—sarcoma	7.95e-05	0.00215	CcSEcCtD
Crizotinib—Constipation—Vincristine—sarcoma	7.93e-05	0.00215	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—sarcoma	7.93e-05	0.00215	CcSEcCtD
Crizotinib—Decreased appetite—Mitoxantrone—sarcoma	7.85e-05	0.00213	CcSEcCtD
Crizotinib—Hypokalaemia—Epirubicin—sarcoma	7.8e-05	0.00211	CcSEcCtD
Crizotinib—Fatigue—Mitoxantrone—sarcoma	7.78e-05	0.00211	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	7.78e-05	0.00211	CcSEcCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—sarcoma	7.76e-05	0.0429	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—sarcoma	7.76e-05	0.0429	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—sarcoma	7.76e-05	0.0429	CbGdCrCtD
Crizotinib—Constipation—Mitoxantrone—sarcoma	7.72e-05	0.00209	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—sarcoma	7.71e-05	0.00209	CcSEcCtD
Crizotinib—LYN—liver—sarcoma	7.71e-05	0.00129	CbGeAlD
Crizotinib—LCK—uterus—sarcoma	7.7e-05	0.00129	CbGeAlD
Crizotinib—BMP2K—bone marrow—sarcoma	7.69e-05	0.00128	CbGeAlD
Crizotinib—FES—lymph node—sarcoma	7.68e-05	0.00128	CbGeAlD
Crizotinib—AXL—uterus—sarcoma	7.67e-05	0.00128	CbGeAlD
Crizotinib—TNK1—liver—sarcoma	7.67e-05	0.00128	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—sarcoma	7.67e-05	0.00128	CbGeAlD
Crizotinib—PTK2B—tendon—sarcoma	7.67e-05	0.00128	CbGeAlD
Crizotinib—TIE1—testis—sarcoma	7.66e-05	0.00128	CbGeAlD
Crizotinib—STK3—testis—sarcoma	7.66e-05	0.00128	CbGeAlD
Crizotinib—Face oedema—Doxorubicin—sarcoma	7.65e-05	0.00207	CcSEcCtD
Crizotinib—RIPK2—tendon—sarcoma	7.6e-05	0.00127	CbGeAlD
Crizotinib—YES1—smooth muscle tissue—sarcoma	7.56e-05	0.00126	CbGeAlD
Crizotinib—Muscular weakness—Epirubicin—sarcoma	7.55e-05	0.00205	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—sarcoma	7.55e-05	0.00205	CcSEcCtD
Crizotinib—PTK2—lymphoid tissue—sarcoma	7.51e-05	0.00125	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—sarcoma	7.51e-05	0.00125	CbGeAlD
Crizotinib—Asthenia—Thiotepa—sarcoma	7.5e-05	0.00203	CcSEcCtD
Crizotinib—AURKA—testis—sarcoma	7.47e-05	0.00125	CbGeAlD
Crizotinib—Infection—Etoposide—sarcoma	7.46e-05	0.00202	CcSEcCtD
Crizotinib—TYK2—lymphoid tissue—sarcoma	7.46e-05	0.00125	CbGeAlD
Crizotinib—Asthenia—Dactinomycin—sarcoma	7.45e-05	0.00202	CcSEcCtD
Crizotinib—IGF1R—liver—sarcoma	7.45e-05	0.00124	CbGeAlD
Crizotinib—TNK2—liver—sarcoma	7.45e-05	0.00124	CbGeAlD
Crizotinib—PTK2B—bone marrow—sarcoma	7.43e-05	0.00124	CbGeAlD
Crizotinib—SLK—cardiac atrium—sarcoma	7.42e-05	0.00124	CbGeAlD
Crizotinib—CSF1R—hematopoietic system—sarcoma	7.41e-05	0.00124	CbGeAlD
Crizotinib—TESK1—testis—sarcoma	7.4e-05	0.00124	CbGeAlD
Crizotinib—SLK—uterus—sarcoma	7.39e-05	0.00123	CbGeAlD
Crizotinib—EPHB4—cardiac atrium—sarcoma	7.37e-05	0.00123	CbGeAlD
Crizotinib—RIPK2—bone marrow—sarcoma	7.36e-05	0.00123	CbGeAlD
Crizotinib—EPHA4—tendon—sarcoma	7.35e-05	0.00123	CbGeAlD
Crizotinib—MAP4K2—liver—sarcoma	7.34e-05	0.00123	CbGeAlD
Crizotinib—EPHB4—uterus—sarcoma	7.33e-05	0.00122	CbGeAlD
Crizotinib—Body temperature increased—Vincristine—sarcoma	7.33e-05	0.00199	CcSEcCtD
Crizotinib—JAK2—cardiac atrium—sarcoma	7.32e-05	0.00122	CbGeAlD
Crizotinib—Skin disorder—Etoposide—sarcoma	7.3e-05	0.00198	CcSEcCtD
Crizotinib—SRC—smooth muscle tissue—sarcoma	7.27e-05	0.00121	CbGeAlD
Crizotinib—MET—lymph node—sarcoma	7.26e-05	0.00121	CbGeAlD
Crizotinib—STK3—liver—sarcoma	7.24e-05	0.00121	CbGeAlD
Crizotinib—TIE1—liver—sarcoma	7.24e-05	0.00121	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—sarcoma	7.23e-05	0.00121	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—sarcoma	7.22e-05	0.00121	CbGeAlD
Crizotinib—Hypokalaemia—Doxorubicin—sarcoma	7.21e-05	0.00196	CcSEcCtD
Crizotinib—MERTK—testis—sarcoma	7.2e-05	0.0012	CbGeAlD
Crizotinib—FGR—lymphoid tissue—sarcoma	7.18e-05	0.0012	CbGeAlD
Crizotinib—SRC—skin of body—sarcoma	7.18e-05	0.0012	CbGeAlD
Crizotinib—Diarrhoea—Thiotepa—sarcoma	7.15e-05	0.00194	CcSEcCtD
Crizotinib—AXL—lymphoid tissue—sarcoma	7.15e-05	0.00119	CbGeAlD
Crizotinib—Body temperature increased—Mitoxantrone—sarcoma	7.14e-05	0.00193	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	7.14e-05	0.00193	CcSEcCtD
Crizotinib—CSF1R—connective tissue—sarcoma	7.13e-05	0.00119	CbGeAlD
Crizotinib—Diarrhoea—Dactinomycin—sarcoma	7.1e-05	0.00192	CcSEcCtD
Crizotinib—TBK1—tendon—sarcoma	7.06e-05	0.00118	CbGeAlD
Crizotinib—PTK2—tendon—sarcoma	7.06e-05	0.00118	CbGeAlD
Crizotinib—AURKA—liver—sarcoma	7.06e-05	0.00118	CbGeAlD
Crizotinib—MAP3K3—cardiac atrium—sarcoma	7.05e-05	0.00118	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—sarcoma	7.05e-05	0.00118	CbGeAlD
Crizotinib—TEK—cardiac atrium—sarcoma	7.05e-05	0.00118	CbGeAlD
Crizotinib—LIMK2—testis—sarcoma	7.04e-05	0.00118	CbGeAlD
Crizotinib—CDK7—lymph node—sarcoma	7.02e-05	0.00117	CbGeAlD
Crizotinib—NUAK2—testis—sarcoma	7.02e-05	0.00117	CbGeAlD
Crizotinib—MAP4K5—uterus—sarcoma	7.02e-05	0.00117	CbGeAlD
Crizotinib—TEK—uterus—sarcoma	7.02e-05	0.00117	CbGeAlD
Crizotinib—TYK2—tendon—sarcoma	7.01e-05	0.00117	CbGeAlD
Crizotinib—TESK1—liver—sarcoma	7e-05	0.00117	CbGeAlD
Crizotinib—Muscular weakness—Doxorubicin—sarcoma	6.99e-05	0.00189	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	6.99e-05	0.00189	CcSEcCtD
Crizotinib—MAP3K2—bone marrow—sarcoma	6.98e-05	0.00117	CbGeAlD
Crizotinib—MAP3K12—testis—sarcoma	6.97e-05	0.00116	CbGeAlD
Crizotinib—FLT3—testis—sarcoma	6.97e-05	0.00116	CbGeAlD
Crizotinib—ACVR1—testis—sarcoma	6.97e-05	0.00116	CbGeAlD
Crizotinib—TAOK2—lymph node—sarcoma	6.97e-05	0.00116	CbGeAlD
Crizotinib—Neutropenia—Epirubicin—sarcoma	6.92e-05	0.00188	CcSEcCtD
Crizotinib—IRAK1—tendon—sarcoma	6.92e-05	0.00116	CbGeAlD
Crizotinib—Dizziness—Thiotepa—sarcoma	6.91e-05	0.00187	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—sarcoma	6.88e-05	0.00187	CcSEcCtD
Crizotinib—TBK1—bone marrow—sarcoma	6.84e-05	0.00114	CbGeAlD
Crizotinib—STK35—testis—sarcoma	6.83e-05	0.00114	CbGeAlD
Crizotinib—ABL1—myometrium—sarcoma	6.82e-05	0.00114	CbGeAlD
Crizotinib—MERTK—liver—sarcoma	6.81e-05	0.00114	CbGeAlD
Crizotinib—TYK2—bone marrow—sarcoma	6.79e-05	0.00113	CbGeAlD
Crizotinib—RPS6KB1—tendon—sarcoma	6.79e-05	0.00113	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—sarcoma	6.79e-05	0.00113	CbGeAlD
Crizotinib—FGR—tendon—sarcoma	6.75e-05	0.00113	CbGeAlD
Crizotinib—Paraesthesia—Etoposide—sarcoma	6.74e-05	0.00183	CcSEcCtD
Crizotinib—EPHB6—cardiac atrium—sarcoma	6.74e-05	0.00113	CbGeAlD
Crizotinib—AXL—tendon—sarcoma	6.72e-05	0.00112	CbGeAlD
Crizotinib—EPHA3—lymph node—sarcoma	6.71e-05	0.00112	CbGeAlD
Crizotinib—ACVR1B—lymph node—sarcoma	6.71e-05	0.00112	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—sarcoma	6.7e-05	0.00112	CbGeAlD
Crizotinib—IRAK1—bone marrow—sarcoma	6.7e-05	0.00112	CbGeAlD
Crizotinib—Weight decreased—Epirubicin—sarcoma	6.7e-05	0.00182	CcSEcCtD
Crizotinib—Dyspnoea—Etoposide—sarcoma	6.7e-05	0.00182	CcSEcCtD
Crizotinib—LIMK2—liver—sarcoma	6.66e-05	0.00111	CbGeAlD
Crizotinib—ABL2—testis—sarcoma	6.65e-05	0.00111	CbGeAlD
Crizotinib—Asthenia—Vincristine—sarcoma	6.65e-05	0.0018	CcSEcCtD
Crizotinib—Vomiting—Thiotepa—sarcoma	6.65e-05	0.0018	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—sarcoma	6.64e-05	0.0018	CcSEcCtD
Crizotinib—NUAK2—liver—sarcoma	6.64e-05	0.00111	CbGeAlD
Crizotinib—Infestation NOS—Epirubicin—sarcoma	6.6e-05	0.00179	CcSEcCtD
Crizotinib—Infestation—Epirubicin—sarcoma	6.6e-05	0.00179	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—sarcoma	6.6e-05	0.00179	CcSEcCtD
Crizotinib—Rash—Thiotepa—sarcoma	6.59e-05	0.00179	CcSEcCtD
Crizotinib—MAP3K12—liver—sarcoma	6.59e-05	0.0011	CbGeAlD
Crizotinib—FLT3—liver—sarcoma	6.59e-05	0.0011	CbGeAlD
Crizotinib—ACVR1—liver—sarcoma	6.59e-05	0.0011	CbGeAlD
Crizotinib—Dermatitis—Thiotepa—sarcoma	6.59e-05	0.00179	CcSEcCtD
Crizotinib—RPS6KB1—bone marrow—sarcoma	6.58e-05	0.0011	CbGeAlD
Crizotinib—BMP2K—testis—sarcoma	6.57e-05	0.0011	CbGeAlD
Crizotinib—ABL1—embryo—sarcoma	6.56e-05	0.0011	CbGeAlD
Crizotinib—Rash—Dactinomycin—sarcoma	6.54e-05	0.00177	CcSEcCtD
Crizotinib—TEK—lymphoid tissue—sarcoma	6.54e-05	0.00109	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—sarcoma	6.54e-05	0.00109	CbGeAlD
Crizotinib—FGR—bone marrow—sarcoma	6.54e-05	0.00109	CbGeAlD
Crizotinib—LCK—bone marrow—sarcoma	6.54e-05	0.00109	CbGeAlD
Crizotinib—Decreased appetite—Etoposide—sarcoma	6.53e-05	0.00177	CcSEcCtD
Crizotinib—CSF1R—smooth muscle tissue—sarcoma	6.53e-05	0.00109	CbGeAlD
Crizotinib—YES1—cardiac atrium—sarcoma	6.51e-05	0.00109	CbGeAlD
Crizotinib—Gastrointestinal disorder—Etoposide—sarcoma	6.48e-05	0.00176	CcSEcCtD
Crizotinib—YES1—uterus—sarcoma	6.48e-05	0.00108	CbGeAlD
Crizotinib—Asthenia—Mitoxantrone—sarcoma	6.48e-05	0.00176	CcSEcCtD
Crizotinib—Fatigue—Etoposide—sarcoma	6.48e-05	0.00176	CcSEcCtD
Crizotinib—SLK—tendon—sarcoma	6.47e-05	0.00108	CbGeAlD
Crizotinib—Neuropathy peripheral—Epirubicin—sarcoma	6.47e-05	0.00175	CcSEcCtD
Crizotinib—STK35—liver—sarcoma	6.46e-05	0.00108	CbGeAlD
Crizotinib—CSF1R—skin of body—sarcoma	6.44e-05	0.00108	CbGeAlD
Crizotinib—TAOK3—cardiac atrium—sarcoma	6.43e-05	0.00107	CbGeAlD
Crizotinib—EPHB4—tendon—sarcoma	6.42e-05	0.00107	CbGeAlD
Crizotinib—Constipation—Etoposide—sarcoma	6.42e-05	0.00174	CcSEcCtD
Crizotinib—STK10—uterus—sarcoma	6.42e-05	0.00107	CbGeAlD
Crizotinib—Neutropenia—Doxorubicin—sarcoma	6.41e-05	0.00174	CcSEcCtD
Crizotinib—JAK3—lymph node—sarcoma	6.4e-05	0.00107	CbGeAlD
Crizotinib—TAOK3—uterus—sarcoma	6.4e-05	0.00107	CbGeAlD
Crizotinib—JAK2—tendon—sarcoma	6.38e-05	0.00107	CbGeAlD
Crizotinib—Upper respiratory tract infection—Doxorubicin—sarcoma	6.37e-05	0.00173	CcSEcCtD
Crizotinib—DCLK1—lymph node—sarcoma	6.36e-05	0.00106	CbGeAlD
Crizotinib—PTK2B—testis—sarcoma	6.35e-05	0.00106	CbGeAlD
Crizotinib—Diarrhoea—Vincristine—sarcoma	6.34e-05	0.00172	CcSEcCtD
Crizotinib—PLK4—lymph node—sarcoma	6.32e-05	0.00106	CbGeAlD
Crizotinib—EPHA2—tendon—sarcoma	6.3e-05	0.00105	CbGeAlD
Crizotinib—RIPK2—testis—sarcoma	6.3e-05	0.00105	CbGeAlD
Crizotinib—ABL2—liver—sarcoma	6.29e-05	0.00105	CbGeAlD
Crizotinib—STK4—lymph node—sarcoma	6.29e-05	0.00105	CbGeAlD
Crizotinib—SLK—bone marrow—sarcoma	6.27e-05	0.00105	CbGeAlD
Crizotinib—SRC—cardiac atrium—sarcoma	6.27e-05	0.00105	CbGeAlD
Crizotinib—Hepatobiliary disease—Epirubicin—sarcoma	6.24e-05	0.00169	CcSEcCtD
Crizotinib—EPHB4—bone marrow—sarcoma	6.22e-05	0.00104	CbGeAlD
Crizotinib—BMP2K—liver—sarcoma	6.21e-05	0.00104	CbGeAlD
Crizotinib—Nausea—Thiotepa—sarcoma	6.21e-05	0.00168	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—sarcoma	6.2e-05	0.00168	CcSEcCtD
Crizotinib—JAK2—bone marrow—sarcoma	6.18e-05	0.00103	CbGeAlD
Crizotinib—Diarrhoea—Mitoxantrone—sarcoma	6.18e-05	0.00167	CcSEcCtD
Crizotinib—Nausea—Dactinomycin—sarcoma	6.16e-05	0.00167	CcSEcCtD
Crizotinib—ABL1—seminal vesicle—sarcoma	6.16e-05	0.00103	CbGeAlD
Crizotinib—MAP3K3—tendon—sarcoma	6.15e-05	0.00103	CbGeAlD
Crizotinib—TEK—tendon—sarcoma	6.15e-05	0.00103	CbGeAlD
Crizotinib—MAP4K5—tendon—sarcoma	6.15e-05	0.00103	CbGeAlD
Crizotinib—Pneumonia—Doxorubicin—sarcoma	6.14e-05	0.00167	CcSEcCtD
Crizotinib—Dizziness—Vincristine—sarcoma	6.13e-05	0.00166	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—sarcoma	6.11e-05	0.00166	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—sarcoma	6.11e-05	0.00166	CcSEcCtD
Crizotinib—EPHA4—testis—sarcoma	6.09e-05	0.00102	CbGeAlD
Crizotinib—YES1—lymphoid tissue—sarcoma	6.04e-05	0.00101	CbGeAlD
Crizotinib—Bradycardia—Epirubicin—sarcoma	6.03e-05	0.00164	CcSEcCtD
Crizotinib—PTK2B—liver—sarcoma	6e-05	0.001	CbGeAlD
Crizotinib—Neuropathy peripheral—Doxorubicin—sarcoma	5.99e-05	0.00162	CcSEcCtD
Crizotinib—STK10—lymphoid tissue—sarcoma	5.99e-05	0.001	CbGeAlD
Crizotinib—MAP3K2—testis—sarcoma	5.97e-05	0.000997	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—sarcoma	5.96e-05	0.000996	CbGeAlD
Crizotinib—MAP4K5—bone marrow—sarcoma	5.96e-05	0.000995	CbGeAlD
Crizotinib—MAP3K3—bone marrow—sarcoma	5.96e-05	0.000995	CbGeAlD
Crizotinib—RIPK2—liver—sarcoma	5.95e-05	0.000994	CbGeAlD
Crizotinib—ALK—lymph node—sarcoma	5.94e-05	0.000992	CbGeAlD
Crizotinib—FER—lymph node—sarcoma	5.94e-05	0.000992	CbGeAlD
Crizotinib—Body temperature increased—Etoposide—sarcoma	5.94e-05	0.00161	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—sarcoma	5.9e-05	0.0016	CcSEcCtD
Crizotinib—Vomiting—Vincristine—sarcoma	5.89e-05	0.0016	CcSEcCtD
Crizotinib—TNK1—lymph node—sarcoma	5.88e-05	0.000982	CbGeAlD
Crizotinib—EPHB6—tendon—sarcoma	5.88e-05	0.000981	CbGeAlD
Crizotinib—ABL1—hematopoietic system—sarcoma	5.86e-05	0.000978	CbGeAlD
Crizotinib—Urinary tract disorder—Epirubicin—sarcoma	5.85e-05	0.00159	CcSEcCtD
Crizotinib—Rash—Vincristine—sarcoma	5.85e-05	0.00158	CcSEcCtD
Crizotinib—PTK2—testis—sarcoma	5.84e-05	0.000976	CbGeAlD
Crizotinib—TBK1—testis—sarcoma	5.84e-05	0.000976	CbGeAlD
Crizotinib—Dermatitis—Vincristine—sarcoma	5.84e-05	0.00158	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—sarcoma	5.84e-05	0.00158	CcSEcCtD
Crizotinib—MAP4K1—lymph node—sarcoma	5.82e-05	0.000972	CbGeAlD
Crizotinib—BMPR1B—lymph node—sarcoma	5.82e-05	0.000972	CbGeAlD
Crizotinib—SRC—lymphoid tissue—sarcoma	5.81e-05	0.000971	CbGeAlD
Crizotinib—Urethral disorder—Epirubicin—sarcoma	5.81e-05	0.00157	CcSEcCtD
Crizotinib—TYK2—testis—sarcoma	5.81e-05	0.00097	CbGeAlD
Crizotinib—Hepatobiliary disease—Doxorubicin—sarcoma	5.78e-05	0.00157	CcSEcCtD
Crizotinib—Vomiting—Mitoxantrone—sarcoma	5.74e-05	0.00156	CcSEcCtD
Crizotinib—IRAK1—testis—sarcoma	5.73e-05	0.000957	CbGeAlD
Crizotinib—Visual impairment—Epirubicin—sarcoma	5.71e-05	0.00155	CcSEcCtD
Crizotinib—TNK2—lymph node—sarcoma	5.71e-05	0.000954	CbGeAlD
Crizotinib—IGF1R—lymph node—sarcoma	5.71e-05	0.000954	CbGeAlD
Crizotinib—Rash—Mitoxantrone—sarcoma	5.69e-05	0.00154	CcSEcCtD
Crizotinib—Dermatitis—Mitoxantrone—sarcoma	5.69e-05	0.00154	CcSEcCtD
Crizotinib—YES1—tendon—sarcoma	5.68e-05	0.000948	CbGeAlD
Crizotinib—MAP3K2—liver—sarcoma	5.64e-05	0.000942	CbGeAlD
Crizotinib—ABL1—connective tissue—sarcoma	5.64e-05	0.000942	CbGeAlD
Crizotinib—MAP4K2—lymph node—sarcoma	5.63e-05	0.00094	CbGeAlD
Crizotinib—STK10—tendon—sarcoma	5.63e-05	0.00094	CbGeAlD
Crizotinib—CSF1R—cardiac atrium—sarcoma	5.63e-05	0.00094	CbGeAlD
Crizotinib—RPS6KB1—testis—sarcoma	5.62e-05	0.000939	CbGeAlD
Crizotinib—TAOK3—tendon—sarcoma	5.61e-05	0.000936	CbGeAlD
Crizotinib—CSF1R—uterus—sarcoma	5.6e-05	0.000935	CbGeAlD
Crizotinib—FGR—testis—sarcoma	5.59e-05	0.000934	CbGeAlD
Crizotinib—LCK—testis—sarcoma	5.59e-05	0.000934	CbGeAlD
Crizotinib—Bradycardia—Doxorubicin—sarcoma	5.58e-05	0.00151	CcSEcCtD
Crizotinib—AXL—testis—sarcoma	5.57e-05	0.00093	CbGeAlD
Crizotinib—TIE1—lymph node—sarcoma	5.55e-05	0.000928	CbGeAlD
Crizotinib—STK3—lymph node—sarcoma	5.55e-05	0.000928	CbGeAlD
Crizotinib—Eye disorder—Epirubicin—sarcoma	5.54e-05	0.0015	CcSEcCtD
Crizotinib—TBK1—liver—sarcoma	5.53e-05	0.000923	CbGeAlD
Crizotinib—PTK2—liver—sarcoma	5.53e-05	0.000923	CbGeAlD
Crizotinib—Nausea—Vincristine—sarcoma	5.51e-05	0.00149	CcSEcCtD
Crizotinib—YES1—bone marrow—sarcoma	5.5e-05	0.000919	CbGeAlD
Crizotinib—Cardiac disorder—Epirubicin—sarcoma	5.5e-05	0.00149	CcSEcCtD
Crizotinib—TYK2—liver—sarcoma	5.49e-05	0.000917	CbGeAlD
Crizotinib—PLK4—Idarubicin—Epirubicin—sarcoma	5.46e-05	0.0302	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—sarcoma	5.46e-05	0.0302	CbGdCrCtD
Crizotinib—Hypoaesthesia—Doxorubicin—sarcoma	5.46e-05	0.00148	CcSEcCtD
Crizotinib—STK10—bone marrow—sarcoma	5.45e-05	0.00091	CbGeAlD
Crizotinib—TAOK3—bone marrow—sarcoma	5.43e-05	0.000907	CbGeAlD
Crizotinib—IRAK1—liver—sarcoma	5.42e-05	0.000905	CbGeAlD
Crizotinib—Urinary tract disorder—Doxorubicin—sarcoma	5.41e-05	0.00147	CcSEcCtD
Crizotinib—AURKA—lymph node—sarcoma	5.41e-05	0.000904	CbGeAlD
Crizotinib—Oedema peripheral—Doxorubicin—sarcoma	5.4e-05	0.00146	CcSEcCtD
Crizotinib—Asthenia—Etoposide—sarcoma	5.39e-05	0.00146	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—sarcoma	5.37e-05	0.00146	CcSEcCtD
Crizotinib—TESK1—lymph node—sarcoma	5.37e-05	0.000896	CbGeAlD
Crizotinib—Nausea—Mitoxantrone—sarcoma	5.36e-05	0.00145	CcSEcCtD
Crizotinib—SLK—testis—sarcoma	5.36e-05	0.000895	CbGeAlD
Crizotinib—Mediastinal disorder—Epirubicin—sarcoma	5.34e-05	0.00145	CcSEcCtD
Crizotinib—EPHB4—testis—sarcoma	5.32e-05	0.000889	CbGeAlD
Crizotinib—RPS6KB1—liver—sarcoma	5.32e-05	0.000888	CbGeAlD
Crizotinib—Arrhythmia—Epirubicin—sarcoma	5.29e-05	0.00143	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—sarcoma	5.28e-05	0.00143	CcSEcCtD
Crizotinib—LCK—liver—sarcoma	5.28e-05	0.000883	CbGeAlD
Crizotinib—FGR—liver—sarcoma	5.28e-05	0.000883	CbGeAlD
Crizotinib—JAK2—testis—sarcoma	5.28e-05	0.000882	CbGeAlD
Crizotinib—AXL—liver—sarcoma	5.26e-05	0.000879	CbGeAlD
Crizotinib—MERTK—lymph node—sarcoma	5.22e-05	0.000872	CbGeAlD
Crizotinib—EPHA2—testis—sarcoma	5.22e-05	0.000872	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—sarcoma	5.22e-05	0.000871	CbGeAlD
Crizotinib—ABL1—smooth muscle tissue—sarcoma	5.16e-05	0.000862	CbGeAlD
Crizotinib—Malnutrition—Epirubicin—sarcoma	5.16e-05	0.0014	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—sarcoma	5.14e-05	0.00139	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—sarcoma	5.12e-05	0.00139	CcSEcCtD
Crizotinib—LIMK2—lymph node—sarcoma	5.11e-05	0.000853	CbGeAlD
Crizotinib—ABL1—skin of body—sarcoma	5.09e-05	0.000851	CbGeAlD
Crizotinib—TEK—testis—sarcoma	5.09e-05	0.00085	CbGeAlD
Crizotinib—MAP3K3—testis—sarcoma	5.09e-05	0.00085	CbGeAlD
Crizotinib—MAP4K5—testis—sarcoma	5.09e-05	0.00085	CbGeAlD
Crizotinib—Cardiac disorder—Doxorubicin—sarcoma	5.09e-05	0.00138	CcSEcCtD
Crizotinib—NUAK2—lymph node—sarcoma	5.09e-05	0.00085	CbGeAlD
Crizotinib—SLK—liver—sarcoma	5.07e-05	0.000846	CbGeAlD
Crizotinib—PLK4—Idarubicin—Doxorubicin—sarcoma	5.05e-05	0.028	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—sarcoma	5.05e-05	0.028	CbGdCrCtD
Crizotinib—ACVR1—lymph node—sarcoma	5.05e-05	0.000844	CbGeAlD
Crizotinib—MAP3K12—lymph node—sarcoma	5.05e-05	0.000844	CbGeAlD
Crizotinib—FLT3—lymph node—sarcoma	5.05e-05	0.000844	CbGeAlD
Crizotinib—Dysgeusia—Epirubicin—sarcoma	5.05e-05	0.00137	CcSEcCtD
Crizotinib—EPHB4—liver—sarcoma	5.03e-05	0.00084	CbGeAlD
Crizotinib—JAK2—liver—sarcoma	4.99e-05	0.000834	CbGeAlD
Crizotinib—Dizziness—Etoposide—sarcoma	4.97e-05	0.00135	CcSEcCtD
Crizotinib—STK35—lymph node—sarcoma	4.95e-05	0.000827	CbGeAlD
Crizotinib—Mediastinal disorder—Doxorubicin—sarcoma	4.94e-05	0.00134	CcSEcCtD
Crizotinib—EPHA2—liver—sarcoma	4.93e-05	0.000824	CbGeAlD
Crizotinib—CSF1R—tendon—sarcoma	4.9e-05	0.000819	CbGeAlD
Crizotinib—Arrhythmia—Doxorubicin—sarcoma	4.9e-05	0.00133	CcSEcCtD
Crizotinib—EPHB6—testis—sarcoma	4.87e-05	0.000813	CbGeAlD
Crizotinib—Vision blurred—Epirubicin—sarcoma	4.86e-05	0.00132	CcSEcCtD
Crizotinib—ABL2—lymph node—sarcoma	4.82e-05	0.000806	CbGeAlD
Crizotinib—TEK—liver—sarcoma	4.81e-05	0.000804	CbGeAlD
Crizotinib—MAP3K3—liver—sarcoma	4.81e-05	0.000804	CbGeAlD
Crizotinib—MAP4K5—liver—sarcoma	4.81e-05	0.000804	CbGeAlD
Crizotinib—Vomiting—Etoposide—sarcoma	4.78e-05	0.00129	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—sarcoma	4.77e-05	0.00129	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—sarcoma	4.77e-05	0.00129	CcSEcCtD
Crizotinib—BMP2K—lymph node—sarcoma	4.76e-05	0.000796	CbGeAlD
Crizotinib—CSF1R—bone marrow—sarcoma	4.75e-05	0.000793	CbGeAlD
Crizotinib—Rash—Etoposide—sarcoma	4.74e-05	0.00128	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—sarcoma	4.73e-05	0.00128	CcSEcCtD
Crizotinib—YES1—testis—sarcoma	4.7e-05	0.000785	CbGeAlD
Crizotinib—Dysgeusia—Doxorubicin—sarcoma	4.67e-05	0.00127	CcSEcCtD
Crizotinib—STK10—testis—sarcoma	4.66e-05	0.000778	CbGeAlD
Crizotinib—TAOK3—testis—sarcoma	4.64e-05	0.000775	CbGeAlD
Crizotinib—Syncope—Epirubicin—sarcoma	4.63e-05	0.00125	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—sarcoma	4.62e-05	0.00125	CcSEcCtD
Crizotinib—PTK2B—lymph node—sarcoma	4.6e-05	0.000769	CbGeAlD
Crizotinib—ABL1—Daunorubicin—Epirubicin—sarcoma	4.59e-05	0.0254	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—sarcoma	4.59e-05	0.0254	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—sarcoma	4.59e-05	0.0254	CbGdCrCtD
Crizotinib—RIPK2—lymph node—sarcoma	4.56e-05	0.000762	CbGeAlD
Crizotinib—Loss of consciousness—Epirubicin—sarcoma	4.53e-05	0.00123	CcSEcCtD
Crizotinib—SRC—testis—sarcoma	4.52e-05	0.000756	CbGeAlD
Crizotinib—Vision blurred—Doxorubicin—sarcoma	4.5e-05	0.00122	CcSEcCtD
Crizotinib—Nausea—Etoposide—sarcoma	4.46e-05	0.00121	CcSEcCtD
Crizotinib—ABL1—cardiac atrium—sarcoma	4.45e-05	0.000743	CbGeAlD
Crizotinib—YES1—liver—sarcoma	4.44e-05	0.000742	CbGeAlD
Crizotinib—ABL1—uterus—sarcoma	4.42e-05	0.000739	CbGeAlD
Crizotinib—Anaemia—Doxorubicin—sarcoma	4.41e-05	0.0012	CcSEcCtD
Crizotinib—EPHA4—lymph node—sarcoma	4.41e-05	0.000737	CbGeAlD
Crizotinib—STK10—liver—sarcoma	4.4e-05	0.000736	CbGeAlD
Crizotinib—TAOK3—liver—sarcoma	4.39e-05	0.000733	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.36e-05	0.00118	CcSEcCtD
Crizotinib—MAP3K2—lymph node—sarcoma	4.33e-05	0.000723	CbGeAlD
Crizotinib—Syncope—Doxorubicin—sarcoma	4.28e-05	0.00116	CcSEcCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—sarcoma	4.28e-05	0.0237	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—sarcoma	4.28e-05	0.0237	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—sarcoma	4.28e-05	0.0237	CbGdCrCtD
Crizotinib—SRC—liver—sarcoma	4.28e-05	0.000714	CbGeAlD
Crizotinib—Leukopenia—Doxorubicin—sarcoma	4.27e-05	0.00116	CcSEcCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—sarcoma	4.25e-05	0.0235	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	4.25e-05	0.0235	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—sarcoma	4.25e-05	0.0235	CbGdCrCtD
Crizotinib—TBK1—lymph node—sarcoma	4.24e-05	0.000708	CbGeAlD
Crizotinib—PTK2—lymph node—sarcoma	4.24e-05	0.000708	CbGeAlD
Crizotinib—Oedema—Epirubicin—sarcoma	4.21e-05	0.00114	CcSEcCtD
Crizotinib—TYK2—lymph node—sarcoma	4.21e-05	0.000703	CbGeAlD
Crizotinib—Loss of consciousness—Doxorubicin—sarcoma	4.2e-05	0.00114	CcSEcCtD
Crizotinib—Infection—Epirubicin—sarcoma	4.18e-05	0.00113	CcSEcCtD
Crizotinib—IRAK1—lymph node—sarcoma	4.15e-05	0.000694	CbGeAlD
Crizotinib—Shock—Epirubicin—sarcoma	4.14e-05	0.00112	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—sarcoma	4.13e-05	0.00112	CcSEcCtD
Crizotinib—ABL1—lymphoid tissue—sarcoma	4.12e-05	0.000689	CbGeAlD
Crizotinib—Skin disorder—Epirubicin—sarcoma	4.09e-05	0.00111	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—sarcoma	4.08e-05	0.000681	CbGeAlD
Crizotinib—CSF1R—testis—sarcoma	4.06e-05	0.000678	CbGeAlD
Crizotinib—LCK—lymph node—sarcoma	4.05e-05	0.000677	CbGeAlD
Crizotinib—FGR—lymph node—sarcoma	4.05e-05	0.000677	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.04e-05	0.00109	CcSEcCtD
Crizotinib—AXL—lymph node—sarcoma	4.03e-05	0.000674	CbGeAlD
Crizotinib—AURKA—Idarubicin—Doxorubicin—sarcoma	3.96e-05	0.0219	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—sarcoma	3.96e-05	0.0219	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—sarcoma	3.96e-05	0.0219	CbGdCrCtD
Crizotinib—Oedema—Doxorubicin—sarcoma	3.9e-05	0.00106	CcSEcCtD
Crizotinib—SLK—lymph node—sarcoma	3.88e-05	0.000649	CbGeAlD
Crizotinib—ABL1—tendon—sarcoma	3.88e-05	0.000648	CbGeAlD
Crizotinib—Infection—Doxorubicin—sarcoma	3.87e-05	0.00105	CcSEcCtD
Crizotinib—EPHB4—lymph node—sarcoma	3.86e-05	0.000644	CbGeAlD
Crizotinib—CSF1R—liver—sarcoma	3.84e-05	0.000641	CbGeAlD
Crizotinib—Shock—Doxorubicin—sarcoma	3.83e-05	0.00104	CcSEcCtD
Crizotinib—JAK2—lymph node—sarcoma	3.83e-05	0.00064	CbGeAlD
Crizotinib—Nervous system disorder—Doxorubicin—sarcoma	3.82e-05	0.00104	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—sarcoma	3.78e-05	0.00103	CcSEcCtD
Crizotinib—EPHA2—lymph node—sarcoma	3.78e-05	0.000632	CbGeAlD
Crizotinib—Paraesthesia—Epirubicin—sarcoma	3.78e-05	0.00102	CcSEcCtD
Crizotinib—ABL1—bone marrow—sarcoma	3.75e-05	0.000627	CbGeAlD
Crizotinib—Dyspnoea—Epirubicin—sarcoma	3.75e-05	0.00102	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—sarcoma	3.71e-05	0.001	CcSEcCtD
Crizotinib—TEK—lymph node—sarcoma	3.69e-05	0.000616	CbGeAlD
Crizotinib—MAP4K5—lymph node—sarcoma	3.69e-05	0.000616	CbGeAlD
Crizotinib—MAP3K3—lymph node—sarcoma	3.69e-05	0.000616	CbGeAlD
Crizotinib—Decreased appetite—Epirubicin—sarcoma	3.66e-05	0.000992	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—sarcoma	3.63e-05	0.000985	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—sarcoma	3.63e-05	0.000984	CcSEcCtD
Crizotinib—Constipation—Epirubicin—sarcoma	3.6e-05	0.000976	CcSEcCtD
Crizotinib—EPHB6—lymph node—sarcoma	3.53e-05	0.000589	CbGeAlD
Crizotinib—Paraesthesia—Doxorubicin—sarcoma	3.5e-05	0.000948	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—sarcoma	3.47e-05	0.000941	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—sarcoma	3.43e-05	0.000929	CcSEcCtD
Crizotinib—CYP3A5—hematopoietic system—sarcoma	3.43e-05	0.000573	CbGeAlD
Crizotinib—YES1—lymph node—sarcoma	3.41e-05	0.000569	CbGeAlD
Crizotinib—Decreased appetite—Doxorubicin—sarcoma	3.39e-05	0.000918	CcSEcCtD
Crizotinib—STK10—lymph node—sarcoma	3.38e-05	0.000564	CbGeAlD
Crizotinib—TAOK3—lymph node—sarcoma	3.36e-05	0.000562	CbGeAlD
Crizotinib—Gastrointestinal disorder—Doxorubicin—sarcoma	3.36e-05	0.000912	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—sarcoma	3.36e-05	0.00091	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—sarcoma	3.33e-05	0.000903	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—sarcoma	3.33e-05	0.000902	CcSEcCtD
Crizotinib—SRC—lymph node—sarcoma	3.28e-05	0.000548	CbGeAlD
Crizotinib—ABL1—testis—sarcoma	3.21e-05	0.000536	CbGeAlD
Crizotinib—Body temperature increased—Doxorubicin—sarcoma	3.08e-05	0.000835	CcSEcCtD
Crizotinib—ABL1—liver—sarcoma	3.03e-05	0.000507	CbGeAlD
Crizotinib—Asthenia—Epirubicin—sarcoma	3.02e-05	0.000819	CcSEcCtD
Crizotinib—CSF1R—lymph node—sarcoma	2.94e-05	0.000492	CbGeAlD
Crizotinib—Diarrhoea—Epirubicin—sarcoma	2.88e-05	0.000781	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—sarcoma	2.79e-05	0.000758	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—sarcoma	2.78e-05	0.000755	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—sarcoma	2.68e-05	0.000726	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—sarcoma	2.67e-05	0.000722	CcSEcCtD
Crizotinib—Rash—Epirubicin—sarcoma	2.65e-05	0.00072	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—sarcoma	2.65e-05	0.000719	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—sarcoma	2.58e-05	0.000698	CcSEcCtD
Crizotinib—CYP3A4—hematopoietic system—sarcoma	2.57e-05	0.00043	CbGeAlD
Crizotinib—Nausea—Epirubicin—sarcoma	2.5e-05	0.000678	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—sarcoma	2.48e-05	0.000671	CcSEcCtD
Crizotinib—Rash—Doxorubicin—sarcoma	2.46e-05	0.000666	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—sarcoma	2.45e-05	0.000665	CcSEcCtD
Crizotinib—ABL1—lymph node—sarcoma	2.33e-05	0.000389	CbGeAlD
Crizotinib—Nausea—Doxorubicin—sarcoma	2.31e-05	0.000627	CcSEcCtD
Crizotinib—ABCB1—myometrium—sarcoma	2.12e-05	0.000354	CbGeAlD
Crizotinib—ABCB1—embryo—sarcoma	2.04e-05	0.000341	CbGeAlD
Crizotinib—ABCB1—seminal vesicle—sarcoma	1.92e-05	0.00032	CbGeAlD
Crizotinib—ABCB1—hematopoietic system—sarcoma	1.82e-05	0.000304	CbGeAlD
Crizotinib—CYP3A5—liver—sarcoma	1.78e-05	0.000297	CbGeAlD
Crizotinib—ABCB1—uterus—sarcoma	1.38e-05	0.00023	CbGeAlD
Crizotinib—CYP3A4—liver—sarcoma	1.33e-05	0.000223	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—sarcoma	1.28e-05	0.000214	CbGeAlD
Crizotinib—ABCB1—bone marrow—sarcoma	1.17e-05	0.000195	CbGeAlD
Crizotinib—ABCB1—testis—sarcoma	9.98e-06	0.000167	CbGeAlD
Crizotinib—ABCB1—liver—sarcoma	9.44e-06	0.000158	CbGeAlD
Crizotinib—ABCB1—lymph node—sarcoma	7.23e-06	0.000121	CbGeAlD
Crizotinib—LCK—Signaling Pathways—PDGFRA—sarcoma	9.75e-07	1.1e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MDM2—sarcoma	9.74e-07	1.1e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—KRAS—sarcoma	9.73e-07	1.09e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—JUN—sarcoma	9.72e-07	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MDM2—sarcoma	9.71e-07	1.09e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTNNB1—sarcoma	9.69e-07	1.09e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—SRC—sarcoma	9.67e-07	1.09e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—sarcoma	9.65e-07	1.09e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTNNB1—sarcoma	9.64e-07	1.08e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—sarcoma	9.64e-07	1.08e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NRAS—sarcoma	9.61e-07	1.08e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—sarcoma	9.56e-07	1.08e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—sarcoma	9.56e-07	1.08e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KIT—sarcoma	9.56e-07	1.07e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—sarcoma	9.48e-07	1.07e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NRAS—sarcoma	9.44e-07	1.06e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—sarcoma	9.42e-07	1.06e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—sarcoma	9.39e-07	1.06e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KDR—sarcoma	9.37e-07	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NRAS—sarcoma	9.3e-07	1.05e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—SRC—sarcoma	9.26e-07	1.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MDM2—sarcoma	9.24e-07	1.04e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1R—sarcoma	9.23e-07	1.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KRAS—sarcoma	9.22e-07	1.04e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KIT—sarcoma	9.22e-07	1.04e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—MDM2—sarcoma	9.21e-07	1.04e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—sarcoma	9.18e-07	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—JUN—sarcoma	9.14e-07	1.03e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KRAS—sarcoma	9.12e-07	1.03e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CREB1—sarcoma	9.1e-07	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTNNB1—sarcoma	9.07e-07	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KRAS—sarcoma	9.03e-07	1.02e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—sarcoma	9.02e-07	1.01e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—SRC—sarcoma	8.98e-07	1.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MDM2—sarcoma	8.97e-07	1.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KRAS—sarcoma	8.96e-07	1.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—sarcoma	8.95e-07	1.01e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—sarcoma	8.92e-07	1e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NRAS—sarcoma	8.9e-07	1e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—sarcoma	8.83e-07	9.93e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—sarcoma	8.79e-07	9.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FOXO1—sarcoma	8.78e-07	9.88e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CREB1—sarcoma	8.78e-07	9.87e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PDGFRB—sarcoma	8.77e-07	9.86e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—SRC—sarcoma	8.76e-07	9.85e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PLCG1—sarcoma	8.76e-07	9.85e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—sarcoma	8.75e-07	9.84e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—sarcoma	8.74e-07	9.83e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—SRC—sarcoma	8.72e-07	9.81e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—sarcoma	8.7e-07	9.79e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—sarcoma	8.7e-07	9.78e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KRAS—sarcoma	8.68e-07	9.76e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—sarcoma	8.67e-07	9.76e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—sarcoma	8.67e-07	9.75e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRAS—sarcoma	8.63e-07	9.71e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PDGFRA—sarcoma	8.63e-07	9.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KIT—sarcoma	8.63e-07	9.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—NRAS—sarcoma	8.63e-07	9.71e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCND1—sarcoma	8.6e-07	9.68e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—sarcoma	8.6e-07	9.67e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—JUN—sarcoma	8.58e-07	9.66e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—sarcoma	8.53e-07	9.59e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CTNNB1—sarcoma	8.52e-07	9.58e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MDM2—sarcoma	8.5e-07	9.56e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—sarcoma	8.48e-07	9.54e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—sarcoma	8.48e-07	9.54e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—JUN—sarcoma	8.47e-07	9.52e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—sarcoma	8.43e-07	9.48e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CTNNB1—sarcoma	8.4e-07	9.45e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—sarcoma	8.39e-07	9.43e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—sarcoma	8.38e-07	9.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CTNNB1—sarcoma	8.37e-07	9.42e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—sarcoma	8.33e-07	9.37e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—sarcoma	8.33e-07	9.37e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—sarcoma	8.29e-07	9.33e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—sarcoma	8.27e-07	9.3e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—sarcoma	8.27e-07	9.3e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—sarcoma	8.25e-07	9.28e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—sarcoma	8.23e-07	9.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CREB1—sarcoma	8.21e-07	9.24e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KDR—sarcoma	8.21e-07	9.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—SRC—sarcoma	8.2e-07	9.22e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MDM2—sarcoma	8.15e-07	9.17e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—sarcoma	8.13e-07	9.14e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—sarcoma	8.11e-07	9.13e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—sarcoma	8.1e-07	9.11e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—sarcoma	8.05e-07	9.05e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—sarcoma	8.04e-07	9.05e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—JUN—sarcoma	8.03e-07	9.03e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—sarcoma	8.01e-07	9.01e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—sarcoma	8.01e-07	9.01e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—JUN—sarcoma	8e-07	9e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CTNNB1—sarcoma	7.97e-07	8.96e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTNNB1—sarcoma	7.94e-07	8.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—sarcoma	7.89e-07	8.87e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—sarcoma	7.87e-07	8.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—sarcoma	7.86e-07	8.84e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—sarcoma	7.84e-07	8.82e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—sarcoma	7.81e-07	8.79e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—JUN—sarcoma	7.8e-07	8.77e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—sarcoma	7.75e-07	8.72e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CTNNB1—sarcoma	7.74e-07	8.7e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SRC—sarcoma	7.7e-07	8.66e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—sarcoma	7.68e-07	8.64e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—sarcoma	7.68e-07	8.63e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—sarcoma	7.66e-07	8.62e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—sarcoma	7.64e-07	8.59e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—sarcoma	7.61e-07	8.56e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SRC—sarcoma	7.59e-07	8.54e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—SRC—sarcoma	7.57e-07	8.51e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KIT—sarcoma	7.56e-07	8.5e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MDM2—sarcoma	7.53e-07	8.47e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—sarcoma	7.5e-07	8.44e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—sarcoma	7.43e-07	8.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—sarcoma	7.43e-07	8.35e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—sarcoma	7.41e-07	8.33e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—sarcoma	7.4e-07	8.32e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—sarcoma	7.37e-07	8.29e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CTNNB1—sarcoma	7.33e-07	8.25e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—sarcoma	7.31e-07	8.22e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—sarcoma	7.28e-07	8.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—sarcoma	7.28e-07	8.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KDR—sarcoma	7.26e-07	8.17e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MDM2—sarcoma	7.26e-07	8.17e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—sarcoma	7.25e-07	8.16e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—sarcoma	7.22e-07	8.12e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—sarcoma	7.22e-07	8.12e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SRC—sarcoma	7.2e-07	8.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CREB1—sarcoma	7.2e-07	8.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—sarcoma	7.18e-07	8.08e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—SRC—sarcoma	7.18e-07	8.07e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—sarcoma	7.12e-07	8.01e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—JUN—sarcoma	7.09e-07	7.97e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTNNB1—sarcoma	7.03e-07	7.91e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—sarcoma	7.03e-07	7.9e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—sarcoma	7.02e-07	7.89e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SRC—sarcoma	6.99e-07	7.87e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—sarcoma	6.93e-07	7.79e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—sarcoma	6.91e-07	7.77e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—sarcoma	6.91e-07	7.77e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—sarcoma	6.9e-07	7.76e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—sarcoma	6.81e-07	7.66e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—sarcoma	6.81e-07	7.66e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—sarcoma	6.81e-07	7.66e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—sarcoma	6.81e-07	7.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MDM2—sarcoma	6.8e-07	7.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—sarcoma	6.79e-07	7.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—sarcoma	6.78e-07	7.63e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—sarcoma	6.75e-07	7.59e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—sarcoma	6.73e-07	7.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KIT—sarcoma	6.69e-07	7.53e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—sarcoma	6.66e-07	7.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—sarcoma	6.63e-07	7.46e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—SRC—sarcoma	6.63e-07	7.46e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—sarcoma	6.61e-07	7.43e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—sarcoma	6.51e-07	7.33e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—sarcoma	6.49e-07	7.3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—sarcoma	6.49e-07	7.3e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—sarcoma	6.45e-07	7.26e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—sarcoma	6.38e-07	7.17e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—sarcoma	6.38e-07	7.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREB1—sarcoma	6.37e-07	7.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—sarcoma	6.36e-07	7.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—sarcoma	6.33e-07	7.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HBA1—sarcoma	6.32e-07	7.11e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—sarcoma	6.32e-07	7.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—sarcoma	6.31e-07	7.1e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—sarcoma	6.31e-07	7.1e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—sarcoma	6.31e-07	7.1e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—sarcoma	6.29e-07	7.08e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—sarcoma	6.29e-07	7.07e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—sarcoma	6.27e-07	7.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—sarcoma	6.27e-07	7.05e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—sarcoma	6.26e-07	7.05e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—sarcoma	6.16e-07	6.93e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—sarcoma	6.14e-07	6.9e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—sarcoma	6.13e-07	6.89e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—sarcoma	6.11e-07	6.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—sarcoma	6.07e-07	6.83e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—sarcoma	5.96e-07	6.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—sarcoma	5.95e-07	6.7e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—sarcoma	5.94e-07	6.69e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—sarcoma	5.94e-07	6.68e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—sarcoma	5.92e-07	6.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—sarcoma	5.91e-07	6.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—sarcoma	5.86e-07	6.59e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—sarcoma	5.81e-07	6.53e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—sarcoma	5.79e-07	6.51e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—sarcoma	5.77e-07	6.49e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—sarcoma	5.67e-07	6.37e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—sarcoma	5.66e-07	6.37e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—sarcoma	5.64e-07	6.35e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—sarcoma	5.59e-07	6.29e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—sarcoma	5.57e-07	6.27e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—sarcoma	5.52e-07	6.2e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—sarcoma	5.49e-07	6.17e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—sarcoma	5.45e-07	6.13e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—sarcoma	5.42e-07	6.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLCG1—sarcoma	5.4e-07	6.07e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—sarcoma	5.34e-07	6.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—sarcoma	5.33e-07	5.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—sarcoma	5.32e-07	5.98e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—sarcoma	5.3e-07	5.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—sarcoma	5.3e-07	5.96e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—sarcoma	5.27e-07	5.93e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—sarcoma	5.26e-07	5.92e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—sarcoma	5.26e-07	5.91e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—sarcoma	5.19e-07	5.83e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—sarcoma	5.17e-07	5.82e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—sarcoma	5.16e-07	5.81e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—sarcoma	5.15e-07	5.79e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—sarcoma	5.14e-07	5.78e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—sarcoma	5.14e-07	5.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—sarcoma	5.1e-07	5.73e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—sarcoma	5.07e-07	5.71e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—sarcoma	5.07e-07	5.7e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—sarcoma	5.05e-07	5.68e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—sarcoma	4.96e-07	5.58e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—sarcoma	4.92e-07	5.54e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—sarcoma	4.86e-07	5.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—sarcoma	4.75e-07	5.34e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—sarcoma	4.71e-07	5.3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—sarcoma	4.69e-07	5.27e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—sarcoma	4.66e-07	5.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—sarcoma	4.64e-07	5.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—sarcoma	4.64e-07	5.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—sarcoma	4.59e-07	5.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—sarcoma	4.58e-07	5.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—sarcoma	4.55e-07	5.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—sarcoma	4.52e-07	5.08e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—sarcoma	4.47e-07	5.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—sarcoma	4.47e-07	5.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—sarcoma	4.39e-07	4.94e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—sarcoma	4.17e-07	4.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—sarcoma	4.16e-07	4.68e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—sarcoma	4.13e-07	4.65e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—sarcoma	4.07e-07	4.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—sarcoma	4e-07	4.5e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—sarcoma	3.99e-07	4.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—sarcoma	3.95e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—sarcoma	3.9e-07	4.39e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—sarcoma	3.84e-07	4.32e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—sarcoma	3.73e-07	4.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—sarcoma	3.68e-07	4.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—sarcoma	3.6e-07	4.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—sarcoma	3.42e-07	3.84e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—sarcoma	3.4e-07	3.83e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—sarcoma	3.27e-07	3.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—sarcoma	3.02e-07	3.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—sarcoma	2.89e-07	3.25e-06	CbGpPWpGaD
